Søgeresultater - Meredith Libeg
- Showing 1 - 3 results of 3
-
1
FDA Approval Summary: Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer With Progression On or After Platinum-Based Chemotherapy af Dickran Kazandjian, Daniel L. Suzman, Gideon M. Blumenthal, Sirisha L. Mushti, Kun He, Meredith Libeg, Patricia Keegan, Richard Pazdur
Udgivet 2016Artigo -
2
Benefit-Risk Summary of Nivolumab for Patients With Metastatic Squamous Cell Lung Cancer After Platinum-Based Chemotherapy af Dickran Kazandjian, Sean Khozin, Gideon M. Blumenthal, Lijun Zhang, Shenghui Tang, Meredith Libeg, Paul G. Kluetz, Rajeshwari Sridhara, Patricia Keegan, Richard Pazdur
Udgivet 2015Artigo -
3
FDA Approval of Nivolumab for the First-Line Treatment of Patients with BRAFV600 Wild-Type Unresectable or Metastatic Melanoma af Julia A. Beaver, Marc R. Theoret, Sirisha L. Mushti, Kun He, Meredith Libeg, Kirsten B. Goldberg, Rajeshwari Sridhara, Amy E. McKee, Patricia Keegan, Richard Pazdur
Udgivet 2017Artigo
Søgeredskaber:
Relaterede emner
Adverse effect
Cancer
Chemotherapy
Confidence interval
Hazard ratio
Immunotherapy
Internal medicine
Medicine
Nivolumab
Oncology
Docetaxel
Interim analysis
Lung cancer
Randomized controlled trial
Surgery
Clinical trial
Dacarbazine
Nausea
Progression-free survival
Progressive disease
Rash
Response Evaluation Criteria in Solid Tumors